UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C., 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
Of Report (Date Of Earliest Event Reported): 7/11/2008
(Exact
Name of Registrant as Specified in its Charter)
Commission
File Number: 0-8092
|
DE
|
|
94-1620407
|
|
(State or
Other Jurisdiction of
|
|
(I.R.S.
Employer
|
|
Incorporation
or Organization)
|
|
Identification
No.)
|
323
Vintage Park Drive, Suite B, Foster City, California 94404
(Address of
Principal Executive Offices, Including Zip Code)
(650)
212-2568
(Registrant’s
Telephone Number, Including Area Code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act(17CFR240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act(17CFR240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act(17CFR240.13e-4(c))
Items to
be Included in this Report
Item
5.02. Departure of
Directors or Principal Officers; Election of Directors; Appointment of Principal
Officers.
(d) Election
of Directors
On July
11, 2008 the board of directors of OXIS International, Inc. appointed William
John Reininger as a member of the board of directors, effective immediately, to
serve until the next annual meeting of stockholders.
Item
9.01. Financial
Statements and Exhibits.
(c) Exhibits
None.
Signature(s)
Pursuant
to the Requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the Undersigned hereunto
duly authorized.
| |
OXIS International,
Inc. |
|
| |
|
|
|
|
Dated
July 16, 2008
|
By:
|
/s/ Marvin
S. Hausman, M.D. |
|
| |
|
Marvin
S. Hausman, M.D. |
|
| |
|
President
& CEO |
|
| |
|
|
|
